共 48 条
- [31] Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage IV Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN StudyCLINICAL LUNG CANCER, 2024, 25 (08) : e389 - e392Ma, JiaPeng, MinBi, JianpingChen, QianPi, GuoliangLi, YingPeng, YiZeng, FanyuXiao, ChuangyingHan, Guang
- [32] Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration RegimensCLINICAL BREAST CANCER, 2014, 14 (06) : 396 - 404Goldstein, Lori J.Gurtler, JayneDel Prete, Salvatore A.Tjulandin, SergeiSemiglazov, Vladimir F.Bayever, ElielMichiels, Bart
- [33] Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of IndonesiaTUBERCULOSIS, 2003, 83 (1-3) : 183 - 186Gravendeel, JMTAsapa, ASBecx-Bleumink, MVrakking, HA
- [34] Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) StudyJACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (07) : 731 - 741Jeong, Young-HoonKim, In-SukPark, YongwhiKang, Min-KyungKoh, Jin-SinHwang, Seok-JaeKwak, Choong HwanHwang, Jin-Yong
- [35] Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialLANCET RESPIRATORY MEDICINE, 2018, 6 (06): : 431 - 441Schoffski, PatrickSufliarsky, JozefGelderblom, HansBlay, Jean-YvesStrauss, Sandra J.Stacchiotti, SilviaRutkowski, PiotrLindner, Lars H.Leahy, Michael G.Italiano, AntoineIsambert, NicolasDebiec-Rychter, MariaSciot, RafVan Cann, ThomasMarreaud, SandrineNzokirantevye, AxelleCollette, SandraWozniak, Agnieszka
- [36] Efficacy of neoadjuvant dose- dense versus standard chemotherapy regimens in ER+HER2-negative breast cancer: a single-center matchedcohort study. Exploratory analysis of immune markersCANCER RESEARCH, 2024, 84 (09)Kovalenko, ElenaArtamonova, ElenaZhulikov, YaroslavKhoroshilov, MaximPetrovskiy, AlexanderVorotnikov, IgorZabotina, TatianaKadagidze, Zaira
- [37] Efficacy of dose-dense and anthracycline-free regimens in neoadjuvant chemotherapy of HER2-positive breast cancer: a single-center matched-cohort study. Preliminary resultsCANCER RESEARCH, 2024, 84 (09)Kovalenko, ElenaZhulikov, YaroslavKhoroshilov, MaximVorotnikov, IgorPetrovskiy, AlexanderArtamonova, Elena
- [38] QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENSCLINICAL CANCER RESEARCH, 2019, 25 (22) : 212 - 212Moore, KathleenSecord, AngelesGeller, MelissaMiller, DavidCloven, NoelleFleming, GiniHendrickson, Andrea E. WahnerAzodi, MasoudDisilvestro, PaulOza, AmitCristea, MihaelaBerek, Jonathan S.Chan, JohnLi, YongSun, KaimingLuptakova, KatarinaMatulonis, Ursula A.Monk, Bradley J.
- [39] A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDBANNALS OF ONCOLOGY, 2017, 28Ajani, J. A.Udrea, A.Sarosiek, T.Shenker, M.Morgan, C.Pikiel, J.Wojcik, E.Swinson, D.Joseph, M.Luft, A.Salek, T.Tournigand, C.Ferry, D.Zhang, Y.Long, A.Kuo, W-L.Gao, L.Kauh, J.Mansoor, W.
- [40] Maintenance treatment of immunotherapy after microwave ablation plus drug-eluting bead bronchial arterial chemoembolization for advanced non-small cell lung cancer: a retrospective single-center cohort studyQUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (05) : 3473 - 3488Xu, ShengBie, Zhi-XinLi, Yuan-MingQi, JingPeng, Jin-ZhaoLi, Xiao-Guang